Derivation and characterization of a patient-derived hiPSC line carrying the HCN2 p.G460D variant with neuronal and cardiac differentiation potential

Background Pathogenic variants in HCN2 , encoding the hyperpolarization-activated cyclic nucleotide-gated channel 2, have recently emerged as a cause of developmental and epileptic encephalopathies (DEEs). Because HCN2 is expressed in both the central nervous and cardiovascular systems, disease mechanisms may extend beyond neuronal dysfunction and involve both neuronal and cardiac tissues. However, the lack of patient-specific human models has limited the investigation of tissue-specific and shared consequences of HCN2 dysfunction and the development of targeted therapeutic approaches. Methods A human induced pluripotent stem cell (hiPSC) line was generated via non-integrating Sendai viral vectors from dermal fibroblasts of a patient with severe drug-resistant DEE carrying the HCN2 c.1379G>A (p.G460D) variant. Following validation of genomic integrity, vector clearance, pluripotency, trilineage potential, and retention of the disease-causing variant, hiPSCs were subjected to directed differentiation toward cortical neurons and cardiomyocytes. Neuronal and cardiac lineage specification, subtype marker profiles, and endogenous HCN2 retention were assessed by RT-qPCR and immunofluorescence. In cardiomyocyte monolayers, functional beating kinetics, rhythm stability, and spatial electromechanical coupling were quantified using video-based motion tracking. Results Reprogramming established a patient hiPSC line carrying the heterozygous HCN2 p. G460D variant with a stable 46,XX karyotype, vector clearance, robust pluripotency, and verified trilineage potential. Directed differentiation yielded deep-layer glutamatergic cortical neurons expressing FOXG1 , MAP2 , BCL11B , and SLC17A7 , forming extensive networks positive for TUBB3, MAP2, and NeuN. In parallel, cardiac differentiation produced functional cardiomyocytes expressing TNNT2 , M YH6 , and MYH7 with organized cTnT, ACTN2, and RYR2 sarcomeric structures. Both lineages retained endogenous HCN2 expression. Video kinematic profiling demonstrated progressive functional maturation of the beating cardiomyocytes, showing a 59.1% reduction in rhythm variability and enhanced spatial electromechanical coupling over time. Conclusion We established the first patient-derived hiPSC platform carrying a pathogenic HCN2 variant associated with DEE. The ability to generate both neuronal and cardiac lineages from the same genetic background provides a valuable translational resource future mechanistic studies, cell-type-specific functional comparisons, and exploratory evaluation of potential therapeutic approaches in HCN2 -related channelopathies.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-11
DOI
https://doi.org/10.3389/fphar.2026.1927604
Primary Topic
Pluripotent Stem Cells Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Derivation and characterization of a patient-derived hiPSC line carrying the HCN2 p.G460D variant with neuronal and cardiac differentiation potential

Serena Calamaio, Francesca Ragona, Marco Villa, Jacopo Cosimo DiFrancesco et al.
Frontiers in Pharmacology
Pluripotent Stem Cells Research
article

Derivation and characterization of a patient-derived hiPSC line carrying the HCN2 p.G460D variant with neuronal and cardiac differentiation potential

Serena Calamaio, Francesca Ragona, Marco Villa, Jacopo Cosimo DiFrancesco, Ginetta Collo, Angela Bentivegna, Barbara Castellotti, Ilaria Rivolta, Rachele Prevostini, Laura Cavalleri, Serena Redaelli
article en

Abstract

Background Pathogenic variants in HCN2 , encoding the hyperpolarization-activated cyclic nucleotide-gated channel 2, have recently emerged as a cause of developmental and epileptic encephalopathies (DEEs). Because HCN2 is expressed in both the central nervous and cardiovascular systems, disease mechanisms may extend beyond neuronal dysfunction and involve both neuronal and cardiac tissues. However, the lack of patient-specific human models has limited the investigation of tissue-specific and shared consequences of HCN2 dysfunction and the development of targeted therapeutic approaches. Methods A human induced pluripotent stem cell (hiPSC) line was generated via non-integrating Sendai viral vectors from dermal fibroblasts of a patient with severe drug-resistant DEE carrying the HCN2 c.1379G>A (p.G460D) variant. Following validation of genomic integrity, vector clearance, pluripotency, trilineage potential, and retention of the disease-causing variant, hiPSCs were subjected to directed differentiation toward cortical neurons and cardiomyocytes. Neuronal and cardiac lineage specification, subtype marker profiles, and endogenous HCN2 retention were assessed by RT-qPCR and immunofluorescence. In cardiomyocyte monolayers, functional beating kinetics, rhythm stability, and spatial electromechanical coupling were quantified using video-based motion tracking. Results Reprogramming established a patient hiPSC line carrying the heterozygous HCN2 p. G460D variant with a stable 46,XX karyotype, vector clearance, robust pluripotency, and verified trilineage potential. Directed differentiation yielded deep-layer glutamatergic cortical neurons expressing FOXG1 , MAP2 , BCL11B , and SLC17A7 , forming extensive networks positive for TUBB3, MAP2, and NeuN. In parallel, cardiac differentiation produced functional cardiomyocytes expressing TNNT2 , M YH6 , and MYH7 with organized cTnT, ACTN2, and RYR2 sarcomeric structures. Both lineages retained endogenous HCN2 expression. Video kinematic profiling demonstrated progressive functional maturation of the beating cardiomyocytes, showing a 59.1% reduction in rhythm variability and enhanced spatial electromechanical coupling over time. Conclusion We established the first patient-derived hiPSC platform carrying a pathogenic HCN2 variant associated with DEE. The ability to generate both neuronal and cardiac lineages from the same genetic background provides a valuable translational resource future mechanistic studies, cell-type-specific functional comparisons, and exploratory evaluation of potential therapeutic approaches in HCN2 -related channelopathies.

Frontiers in PharmacologyVol. 17
IRCCS Policlinico San Donato (IT), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), University of Milano-Bicocca (IT), University of Brescia (IT)
Pluripotent Stem Cells Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon